Last reviewed · How we verify
NBP607
NBP607 is a novel therapeutic agent in development by SK Chemicals, currently in phase 3 clinical trials.
At a glance
| Generic name | NBP607 |
|---|---|
| Sponsor | SK Chemicals Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding the specific mechanism of action for NBP607. As a phase 3 candidate from SK Chemicals, it represents an advanced-stage investigational drug, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases.
Approved indications
Common side effects
Key clinical trials
- Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 Months (PHASE3)
- Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects (PHASE3)
- Safety, Tolerability and Immunogenicity of an Trivalent Inactivated Cell-Culture Influenza Vaccine in Healthy Adults (PHASE1)
- Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months (PHASE3)
- Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents (PHASE3)
- Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents (PHASE3)
- Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NBP607 CI brief — competitive landscape report
- NBP607 updates RSS · CI watch RSS
- SK Chemicals Co., Ltd. portfolio CI